Amylyx Pharmaceuticals (AMLX) said late Thursday it has commenced an underwritten public offering of common shares.

Amylyx plans to give the underwriter a 30-day option to buy up to an additional 15% of the shares offered.

The company said the proceeds will be used to support commercialization, pipeline programs, working capital and general corporate needs.